Related Experiment Video
Updated: May 9, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Palbociclib stimulates CD8 + T cell response in triple-negative breast cancer via regulating phosphoglycerate
Yuanyuan Sun1,2,3,4,5, Yaqing Li1,2,3,4,5, Yunwei Han1,2,3,4,5
1Department of Breast Pathology and Lab, Tianjin Medical University Cancer Institute & Hospital.
Abstract:
CDK4/6 inhibitors are applied for the treatment of breast cancer. The purpose of this study was to explore the effects of palbociclib (PALB) on triple-negative breast cancer. An in vivo assay was applied to determine the effects of PALB on breast cancer. Gene expression was detected using immunohistochemistry. mRNA levels were detected using reverse transcription-quantitative PCR. Protein expression was detected using western blot. The expansion of CD8 + T cell subsets was detected using flow cytometry. We found that PALB treatment promoted the persistence of CD8 + T cells, manifested by the maintenance of stem-like CD8 + T cells and effector T cells. Moreover, PALB downregulated phosphoglycerate dehydrogenase (PHGDH), high levels of which predicted poor prognosis of breast cancer patients. Moreover, overexpression of PHGDH antagonized the effects of PALB and suppressed the persistence of CD8 + T cells. Additionally, PALB enhanced the effects of anti-PD1 immunotherapy and suppressed the tumor growth of breast cancer. In summary, PALB promoted the maintenance of CD8 + memory precursors in breast cancer via downregulating PHGDH.
More Related Videos
11:06Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
Published on: May 20, 2015
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Related Concept Videos
Inhibition of Cdk Activity
Positive Regulator Molecules
Targeted Cancer Therapies
There are several types of targeted therapies against...
Negative Regulator Molecules
PI3K/mTOR/AKT Signaling Pathway